Brief Summary
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Protocol Interventions
Biological: AZD0240: Autologous, engineered T Cells targeting KRAS G12D